Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers.
Yohei AndoMohamad DboukTakeichi YoshidaElizabeth Abou DiwanHelena SabaAli DboukKanako YoshidaNicholas J RobertsAlison P KleinRichard BurkhartJin HeRalph H HrubanMichael G GogginsPublished in: JCO precision oncology (2024)
Patients with pancreatic and nonpancreatic periampullary cancer have a similar prevalence of pathogenic cancer susceptibility variants. Germline susceptibility testing should be considered for patients with any periampullary cancer.